Contents

Editors xii
Contributors xvi
Reviewers xxii
Abbreviations xxv
Acknowledgements xxxiii
Preface xxxiv

Section 1: Introduction to immunology and immunotherapy

1.1 Immune Checkpoints 3
   Definition 3
   Immune Synapse 4
   Technical Procedures 7
   Predictive and/or Prognostic Biomarkers of (Potential)
     Clinical Relevance 8
   Clinical Results 10
   Potential Future Developments 13
   Further Reading 14

1.2 Adoptive T Cell Therapy 15
   Naturally Occurring Tumour-specific T Cells 15
   Genetically Modified T Cells 17
   Concluding Remarks 22
   Further Reading 22
1.3 **Vaccines (Dendritic Cell Vaccines, Peptide Vaccines, DNA Vaccines, RNA Vaccines, Oncolytic Viruses)**

Definition (Introduction to the Concept and Development of Cancer Vaccine Strategies) 23
Essential Processes Involved 26
Dendritic Cell Vaccines 27
Peptide Vaccines 31
DNA Vaccines 34
RNA Vaccines 35
Oncolytic Viruses 36
Predictive and/or Prognostic Biomarkers of (Potential) Clinical Relevance 37
Potential Future Developments 37
Further Reading 40

1.4 **Biomarkers for Immunotherapy**

Introduction 43
Biological Background for Biomarkers in Immunotherapy 43
Future Immuno-oncology Biomarker Strategies 53
Conclusion 53
Further Reading 54

1.5 **Resistance to Immunotherapy**

Introduction 56
Tumour-intrinsic Mechanisms of Immune Checkpoint Inhibitor Resistance 57
Tumour-extrinsic Mechanisms of Immune Checkpoint Inhibitor Resistance 63
Environmental Host Factors 64
Unmet Needs 66
Further Reading 67

**Section 2: Immunotherapies in specific disease groups – State of the art**

2.1 **Melanoma**

Overview of Immunotherapy in Melanoma 73
Clinical Results 126  
Potential Future Developments 129  
Further Reading 131  

2.3.4 Other Thoracic Malignancies: Thymic Malignancies and Others 133  
Thymic Malignancies 133  
Other Rare Thoracic Malignancies 138  
Further Reading 140  

2.4 Genitourinary Malignancies 142  
2.4.1 Renal Cancer 142  
Introduction 142  
Clinical Results 143  
Potential Future Developments 148  
Conclusion 151  
Further Reading 152  

2.4.2 Bladder Cancer 154  
Introduction and Context 154  
Clinical Results 156  
Potential Future Developments 161  
Further Reading 164  

2.5 Gastrointestinal Malignancies 166  
2.5.1 Microsatellite Instability-high 167  
Pathogenesis of Microsatellite Instability 167  
Who Does This Apply To? 168  
Clinical, Pathological and Genetic Criteria Involved in Detection of Mismatch Repair Deficiency 169  
Historical Prognostic and Predictive Value of MSI 171  
Clinical Rationale of Using MSI as a Predictive Biomarker for Programmed Cell Death Protein 1 Antibody Response 172  
Clinical Implications 173  
Further Reading 175
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.5.2 Gastric and Oesophageal Malignancies</td>
<td>178</td>
</tr>
<tr>
<td>Introduction</td>
<td>178</td>
</tr>
<tr>
<td>The Immune Environment in Gastro-oesophageal Cancer</td>
<td>178</td>
</tr>
<tr>
<td>Immune Checkpoint Blockade in Gastro-oesophageal Cancer</td>
<td>179</td>
</tr>
<tr>
<td>Squamous Oesophageal Cancer</td>
<td>187</td>
</tr>
<tr>
<td>Conclusions and Future Directions</td>
<td>188</td>
</tr>
<tr>
<td>Further Reading</td>
<td>189</td>
</tr>
<tr>
<td>2.5.3. Hepatocellular Carcinoma</td>
<td>191</td>
</tr>
<tr>
<td>Introduction</td>
<td>191</td>
</tr>
<tr>
<td>HCC Immunobiology</td>
<td>192</td>
</tr>
<tr>
<td>Current Landscape of Immune Checkpoint Inhibition in HCC</td>
<td>193</td>
</tr>
<tr>
<td>Alternative Immunotherapeutic Strategies</td>
<td>198</td>
</tr>
<tr>
<td>Future Directions and Issues Specific to HCC</td>
<td>199</td>
</tr>
<tr>
<td>Conclusions</td>
<td>201</td>
</tr>
<tr>
<td>Further Reading</td>
<td>202</td>
</tr>
<tr>
<td>2.6 Immunotherapy in Head and Neck Tumours (HPV+ and HPV-)</td>
<td>203</td>
</tr>
<tr>
<td>Immunotherapy in Head and Neck Cancer – the Rationale</td>
<td>203</td>
</tr>
<tr>
<td>Immunotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma</td>
<td>205</td>
</tr>
<tr>
<td>Immunotherapy in Recurrent/Metastatic Head and Neck Cancer – Evidence and Future Directions</td>
<td>208</td>
</tr>
<tr>
<td>Immuno-oncology in Head and Neck Cancer: Predictive Biomarkers?</td>
<td>210</td>
</tr>
<tr>
<td>Conclusion</td>
<td>214</td>
</tr>
<tr>
<td>Further Reading</td>
<td>214</td>
</tr>
<tr>
<td>2.7 Immunotherapies in Lymphoma</td>
<td>217</td>
</tr>
<tr>
<td>Introduction</td>
<td>217</td>
</tr>
<tr>
<td>Monoclonal Antibodies</td>
<td>217</td>
</tr>
<tr>
<td>Interferons</td>
<td>219</td>
</tr>
<tr>
<td>Vaccination</td>
<td>220</td>
</tr>
<tr>
<td>Immune Checkpoint Inhibitors</td>
<td>221</td>
</tr>
<tr>
<td>Chimeric Antigen Receptor-T cell Therapy</td>
<td>224</td>
</tr>
<tr>
<td>Bispecific Antibodies</td>
<td>227</td>
</tr>
<tr>
<td>Further Reading</td>
<td>228</td>
</tr>
</tbody>
</table>
2.8 Gynaecological Malignancies 230
The Role of Immunotherapy in Ovarian Cancer 230
The Role of Immunotherapy in Cervical Cancer 235
The Role of Immunotherapy in Endometrial Cancer 238
Further Reading 241

Section 3: Implications for clinical practice

3.1 Management of Adverse Events Related to Immune Checkpoint Blockade 245
Definition 245
Processes Involved 245
Global Management 246
Clinical Results 247
Further Reading 256

3.2 Immune Checkpoint Blockade: Response Patterns and Assessment of Response 258
The Problem 258
Response Patterns in Immunotherapy 258
Criteria for Response 261
Potential Future Developments 264
Further Reading 266

3.3 Immunotherapy in Special Populations 267
Introduction 267
Clinical Results/Patient Groups 268
Potential Future Developments 275
Further Reading 276

3.4 Cancer Immunotherapy Trials: Challenges and Opportunities 278
Introduction 278
Lessons from Pre-checkpoint Inhibitor Immunotherapy 280
Optimising Contemporary Immunotherapy Clinical Trials 282
Summary 285
Further Reading 286
3.5 Future Perspectives 287
   Introduction 287
   Precision Immunotherapy 288
   Conclusions 294
   Further Reading 295

Index 296